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Background: Numerous studies have implicated the aryl hydrocarbon receptor (AhR) as a potential therapeutic
target for several human diseases, including estrogen receptor alpha (ERα) positive breast cancer. Aminoflavone
(AF), an activator of AhR signaling, is currently undergoing clinical evaluation for the treatment of solid tumors. Of
particular interest is the potential treatment of triple negative breast cancers (TNBC), which are typically more
aggressive and characterized by poorer outcomes. Here, we examined AF’s effects on two TNBC cell lines and the
role of AhR signaling in AF sensitivity in these model cell lines.
Methods: AF sensitivity in MDA-MB-468 and Cal51 was examined using cell counting assays to determine growth
inhibition (GI50) values. Luciferase assays and qPCR of AhR target genes cytochrome P450 (CYP) 1A1 and 1B1 were
used to confirm AF-mediated AhR signaling. The requirement of endogenous levels of AhR and AhR signaling for
AF sensitivity was examined in MDA-MB-468 and Cal51 cells stably harboring inducible shRNA for AhR. The mechanism
of AF-mediated growth inhibition was explored using flow cytometry for markers of DNA damage and apoptosis, cell
cycle analysis, and β-galactosidase staining for senescence. Luciferase data was analyzed using Student’s T test.
Three-parameter nonlinear regression was performed for cell counting assays.
Results: Here, we report that ERα-negative TNBC cell lines MDA-MB-468 and Cal51 are sensitive to AF. Further, we
presented evidence suggesting that neither endogenous AhR expression levels nor downstream induction of AhR
target genes CYP1A1 and CYP1B1 is required for AF-mediated growth inhibition in these cells. Between these two ERα
negative cell lines, we showed that the mechanism of AF action differs slightly. Low dose AF mediated DNA damage,
S-phase arrest and apoptosis in MDA-MB-468 cells, while it resulted in DNA damage, S-phase arrest and cellular
senescence in Cal51 cells.
Conclusions: Overall, this work provides evidence against the simplified view of AF sensitivity, and suggests that AF
could mediate growth inhibitory effects in ERα-positive and negative breast cancer cells, as well as cells with impaired
AhR expression and signaling. While AF could have therapeutic effects on broader subtypes of breast cancer, the
mechanism of cytotoxicity is complex, and likely, cell line- and tumor-specific.
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Aside from non-melanoma skin cancers, breast cancer is
the most common cancer among women worldwide, with
nearly 1.4 million new cases diagnosed in 2008 [1]. Often,
breast cancers are characterized by their expression of
hormone receptors (estrogen receptor, ER; progesterone
receptor, PR; or human epidermal growth factor receptor
2, HER2). Cancers expressing one or more of these recep-
tors have the potential to be treated with targeted therap-
ies, including tamoxifen and trastuzumab. On the other
hand, there is no specific treatment regimen for patients
whose cancers lack these three receptors, so called triple-
negative breast cancers (TNBC), which tend to be clinic-
ally aggressive with a trend of poorer outcomes [2]. Thus,
it is critical to develop and explore therapeutic options
that may be of use to these patients.
Aminoflavone (AF; 4H-1-benzopyran-4-one, 5-amino-
2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl, NSC
686288) is a synthetic flavonoid compound [3]. Similar
compounds are frequently found in fruits and vegetables,
and have a variety of effects within the body, including
reported cytostatic, apoptotic, anti-inflammatory, anti-
angiogenic, and estrogenic activities [4]. The National
Cancer Institute’s 60 human tumor cell line anticancer
drug screen revealed that AF mediated growth inhibition
in numerous renal, breast and ovarian tumor cell lines,
and produced a unique “fingerprint” of activity in the
COMPARE algorithm, unlike any other group of anti-
tumor compounds [5-7]. A pattern uncovered in AF’s
differential activity in human breast cancer cell lines was
the exquisite sensitivity of cells expressing estrogen re-
ceptor alpha (ERα), such as MCF7 and T47D, and resist-
ance exhibited by cells lacking ERα expression, including
MDA-MB-231, Hs578T, and BT-549. When mice bear-
ing ERα-positive MCF7 xenografts were treated with AF,
tumor growth was inhibited [8]. Further, it has been
shown that AF-resistant and ERα negative cell lines
MDA-MB-231 and Hs578T may be re-sensitized to AF
through co-treatment with vorinostat, which reactivates
ERα expression and AhR-mediated CYP1A1 activity [9].
These data imply that ERα-positive cancers might ex-
hibit enhanced sensitivity to AF as compared with ERα-
negative cancers.
Before the cytotoxic mechanism of AF was studied in
ERα-positive breast cancer cell lines, other flavonoid ana-
logs had been synthesized/extracted and examined [10-12].
Growth inhibition exerted by these related compounds is
attributed to a number of processes, including topisome-
rase inhibition, blocking of tubulin polymerization, and
decreases in protein kinase activity [13-15]. However, AF’s
COMPARE fingerprint differs from compounds with these
mechanisms of action, suggesting that the antiproliferative
activity of AF is the result of a different mechanism [7,8].
Because flavonoid compounds have been shown to bindthe intracellular aryl hydrocarbon receptor (AhR) and acti-
vate the AhR signaling pathway, one suggestion to explain
AF’s activity pattern is metabolic activation by the AhR and
its target genes, specifically the 1A isoforms of cytochome
P450 (CYP) enzymes [7,8,16,17]. An AhR-deficient clone
of MCF7 that was generated by continuous exposure to
100nM benzo [a] pyrene for six to nine months (AhR100)
has been shown to be rendered resistant to AF [8,18,19].
Further, previous studies revealed that AF is metabolized
by CYP1A1 and, to a lesser extent, 1A2 and 1B1, and that
this metabolism produces hydroxylamine species [7,8,17].
It has also been shown that AF induces expression of sulfo-
transferase (SULT) 1A1 enzymes in AF-sensitive MCF7
cells, and that transfection of SULT1A1 into resistant
MDA-MB-231 cells restores sensitivity [20]. Correlations
between high activity CYP1A1 and SULT1A1 alleles and
sensitivity to AF have also been made in chinese hampster
cells engineered to express various polymorphisms of these
genes [21]. AF metabolites, presumably though the CYP/
SULT driven bioactivation pathway, have been shown to be
DNA damaging agents, inducing DNA-protein crosslinks,
cytokeratin-RNA crosslinks, phosphorylation of p53,in-
creased expression of p21, γ-Histone 2AX (γ-H2AX),
reactive oxygen species-mediated apoptosis, and S-phase
arrest in sensitive populations of cells [7,8,17,19,20,22-25].
These studies implicated that AhR might, at least in part,
mediate the cytotoxic and DNA damaging effects of AF.
AhR is a ligand-activated transcription factor that is
known for its role in mediating the cellular response to
dioxins, polycyclic aromatic hydrocarbons, and related
compounds [26,27]. Upon ligand binding, conformational
changes occur, allowing AhR’s nuclear localization signal
to be exposed. This leads to translocation of AhR to the
nucleus, where AhR dimerizes with aryl hydrocarbon
receptor nuclear translocator (ARNT), and binds to dioxin
responsive elements (DREs), resulting in regulation of
target genes [28,29]. Of particular importance regarding
the bioactivation of AF are AhR target genes in the CYP1A
family [7,8,17]. In addition to increasing CYP1A1/1A2/
1B1 expression, AF induces nuclear translocation of AhR
and stimulates protein-DNA complexes formed on DREs
in AF-sensitive MCF7 human breast cancer cells, suggest-
ing that AF is an AhR agonist [8]. Further, localization of
AhR in the cellular cytoplasm has been shown to correlate
with AF sensitivity [8,19]. Interestingly, it has also been
shown that AF inhibits hypoxia inducible factor 1α
(HIF1α), a protein which may interact with AhR [30].
However, it remains to be determined whether AhR
expression and downstream gene activation serve as
determinants for AF sensitivity, particularly in ERα-
negative human cell lines.
The objective of this study was to further investigate
potential biomarkers of AF sensitivity, including ERα ex-
pression, AhR expression, and AhR signaling in human
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ERα-negative human breast cancer cell lines, MDA-MB-
468 and Cal51, exhibit sensitivity to AF, and the sensitiv-
ity is retained after knockdown of AhR protein [23] .
While both cell lines express high levels of endogenous
AhR protein, they display differential abilities to induce
AhR target genes CYP1A1 and CYP1B1, yet the cytotox-
icity of AF in these cell lines remains similar. To our
knowledge, and using the cBio portal maintained by the
Computational Biology Center at Memorial Sloan-
Kettering Cancer Center, neither of these human breast
cancer cell lines harbors a mutation in the AhR gene.
These results suggest that neither expression of ERα and
AhR nor CYP induction is necessarily predictive of AF
sensitivity. Further, we showed that AF exerts its anti-
proliferative activity in a cell-type specific manner: low
dose AF treatment causes DNA damage, S-phase arrest
and apoptosis in MDA-MB-468 AhR knockdown cells
(MDA-MB-468shAhR), while causing DNA damage, S-
phase arrest, and a senescent-like phenotype in Cal51
AhR knockdown cells (Cal51shAhR).
Methods
Chemicals
Doxycycline (Dox) was obtained from Clontech (Mountain
View, CA). β-Naphthoflavone (BNF) was obtained from
Sigma (St. Louis, MO). Aminoflavone (AF) was obtained
from the Developmental Therapeutics Program Repository
of the National Cancer Institute at Frederick (Frederick,
MD). BNF and AF were stored in dimethyl sulfoxide
(DMSO). Triton X-100 was obtained from Fisher (Fair
Lawn, NJ), protease inhibitors were obtained from Roche
Scientific (Basel, Switzerland), and benzonase was obtained
from Novagen (San Diego, CA). All other chemicals were
obtained from Sigma (St. Louis, MO).
Cell culture
Cell culture media were obtained from Invitrogen
(Carlsbad, CA). MDA-MB-468, Cal51, 293 T, and 101 L
hepatoma cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) with 10% Gibco Fetal Bovine
Serum (FBS, Invitrogen) at 37°C and 5% CO2. MDA-
MB-468shAhR and Cal51shAhR were maintained in
DMEM with 10% Tet-System Approved FBS (Clontech)
at 37°C and 5% CO2. MDA-MB-468 cells are mammary
adenocarcinoma cells from a pleural effusion and were
purchased from ATCC (Manassas, VA). Cal51 cells are
also mammary adenocarcinoma cells from a plural effu-
sion, but they exhibit a normal karyotype [31]. Cal51 was
purchased from DSMZ (Braunschweig, Germany). 101 L
hepatoma cells harbor a stably transfected luciferase re-
porter driven by three upstream DREs, and were obtained
from Dr. Christopher Bradfield (Madison, WI), initially ac-
quired from the laboratory of Dr. Robert Tukey (SanDiego, CA) [32]. Parental cell lines were maintained in
our laboratory for less than six months after resuscitation.
Dioxin responsive element reporter assays
101 L cells were seeded in triplicate at 2.2 × 104 cells/well
on a clear 48-well tissue culture plate in phenol red-free
DMEM with 5% charcoal-stripped FBS. After 24 hours,
media were removed and replaced with media containing
0.1% dimethyl sulfoxide (DMSO) or a range of AF doses
(100nM, 500nM, 1 μM, 10 μM). After 18 hours of com-
pound treatment, the cells were washed with 50 μL 1×
PBS (Gibco, Invitrogen) and lysed with 50 μL Tropix lysis
buffer (100 mM K2HPO4, 0.2% Triton X-100, pH 7.8, Ap-
plied Biosystems). Cell lysate was mixed 1:1 with luciferase
substrate (Promega, Madison, WI), and luminescence was
measured with a 700-nm filter on a Victor X5 microplate
reader (PerkinElmer, Waltham, MA). The Bradford
method (Bio-Rad) was used to measure total protein in
each sample. Raw luciferase data was normalized to both
total protein and background luciferase expression in the
DMSO control samples and expressed as fold-increase
over DMSO.
Inducible knockdown of AhR by lentiviral infection
pSUPER vectors were constructed using two previously
published siRNA sequences directed toward the AhR, 5′
CAGACAGUAGUCUGUUAUA 3′ and 5′CGUUUAC
CUUCAAACUUUA 3′, by standard cloning procedures
[33-35]. The siRNA cassette downstream of the H1 pro-
moter was sequenced to confirm accuracy (University of
Wisconsin Biotechnology Center, Madison, WI), excised
from pSUPER, and subcloned into the lentiviral vector
pLVTHM. Viral particles containing shAhR vectors were
created by transfecting host 293 T cells with vectors en-
coding for VSVG, a lentiviral vector coat protein, PAX2,
a packaging plasmid, and pLVTHM-shAhR using stand-
ard protocols [36]. Briefly, subconfluent 293 T cells were
transfected with 0.5 μg VSVG, 1 μg PAX2, and 1.5 μg
pLVTHM-shAhR using Trans-IT LT1 transfection reagent
(Mirus Bio, Madison, WI). After six hours, medium was
changed and recombinant lentivirus vectors were harvested
24 hours later. Using a similar protocol, pLV-tTR-KRAB
recombinant lentivirus was produced. pLV-tTR-KRAB
encodes a tetracycline (Tet)- controlled hybrid protein con-
taining the Tet repressor (tTR) and the Krüppel associated
box (KRAB) domain of human Kox1 [37,38]. The purpose
of KRAB in Tet-responsive systems is described elsewhere
(34). MDA-MB-468 and Cal51 cells were seeded subconflu-
ently in a six-well tissue culture plate at 37°C and 5% CO2.
Twenty-four hours later, media were removed and replaced
with 1 mL of DMEM supplemented with 10% FBS contain-
ing recombinant pLV-tTR-KRAB and 5 μg/mL polybrene.
After allowing two passages for recovery, the MDA-MB-
468 and Cal51 cells were subjected to the same protocol,
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shAhR lentiviruses, producing MDA-MB-468shAhR and
Cal51shAhR cell lines.
Western blot analysis
MDA-MD-468shAhR and Cal51shAhR were treated for
seven days with vehicle or 750 ng/mL doxycycline (Dox)
in DMEM with 10% Tet-Approved FBS. After treatment,
cells were collected by trypsinization, washed with 1×
PBS (Gibco, Invitrogen), and lysed using Triton X-100
lysis buffer (50 mM Tris pH 8.0, 400 mM NaCl, 10% gly-
cerol, 0.5% triton X-100, protease inhibitors, and benzo-
nase). Total protein concentration was measured using
the Bradford method (BioRad), and 20 μg of protein was
resolved using SDS-PAGE on 8% polyacrylamide gels.
Protein was transferred to a nitrocellulose membrane at
4°C for one hour at 0.35A. Membranes were blocked
with 5% nonfat milk in PBS + 0.1% Tween for one hour at
room temperature, then incubated with 1:10,000 anti-AhR
antibody (Santa Cruz, sc-5579) or 1:10,000 anti-β-Actin
(Sigma, A5316) overnight at 4°C. Membranes were incu-
bated with 1:10,000 goat anti-rabbit HRP or anti-mouse
HRP secondary antibody for one hour at room temperature.
Enhanced chemiluminescence reagents (Thermo Scientific)
were applied to the membranes prior to exposure to x-ray
film (Kodak).
Cell counting assays
MDA-MB-468, MDA-MB-468shAhR, MCF7, MDA-MB-
231, Cal51, and Cal51shAhR were seeded at 20,000 cells/
well (MDA-MB-468, MDA-MB-468shAhR, MDA-MB-
231) and 15,000 cells/well (MCF7, Cal51, Cal51shAhR),
each in triplicate 12-well tissue culture plates in DMEM+
10% FBS at 37°C and 5% CO2. AhR knockdown cells were
pretreated with vehicle or 750 ng/mL Dox for seven days
prior to seeding in 12-well tissue culture plates to achieve
knockdown of AhR. During AF treatment, vehicle/Dox
treatments were continued. All cell lines tested were
treated with AF for seven days prior to analysis. Approxi-
mate GI50 value, which is the concentration of compound
that inhibits cell growth by 50% compared to control, was
calculated using GraphPad Prism Software (Version 5.04;
Graph-Pad Software Inc., San Diego, CA) and a three-
parameter log versus inhibition nonlinear regression. GI50
values are expressed as the 95% confidence interval.
Gene expression analysis
MDA-MB-468, MDA-MB-468shAhR, Cal51, and Cal51-
shAhR cells were cultured in phenol red-free DMEM+
10% charcoal stripped FBS at 37°C and 5% CO2 for three
days prior to experiment to remove residual estrogens.
Triplicate 80% confluent six cm tissue culture dishes of
MDA-MB-468 and Cal51 were treated with 0.1% DMSO,
1 μM AF, or 1 μM BNF for six hours. MDA-MB-468shAhR and Cal51shAhR were pretreated with vehicle
or 750 ng/mL Dox for seven days prior to seeding onto
triplicate six cm tissue culture dishes, and then treated
with 0.1% DMSO, 1 μM AF, or 1 μM BNF for six hours in
the presence or absence of 750 ng/mL Dox. Total RNA
was extracted using HP Total RNA Kit (VWR Scientific,
West Chester, PA) according to the manufacturer’s proto-
col. Two micrograms of RNA were reverse transcribed
using Superscript II RT according to the manufacturer’s
protocol (Invitrogen). Fast Start Universal SYBR Green
Master Mix (Roche) was used to perform qPCR for
CYP1A1 on a BioRad CFX-96 instrument, using RPL13A
as a housekeeping gene (BioRad). The primer sequences
are as follows: CYP1A1 For 5′TGCAGA AGATGGTCA
AGGAG 3′, CYP1A1 Rev 5′ AGCTCCAAGAGGTCCAA
GA 3′. CYP1B1 For 5′CTGGATTTGGAGAACGTACCG
3′, CYP1B1 Rev 5′TGATCCAATTCTGCCTGCAC 3′.
SULT1A1 For 5′GGCCTGATGACCTGCTCATC 3′.
SULT1A1 Rev 5′TCATGTCCAGAATCTGGCTTACC 3′.
RPL13A For 5′ CATCGTGGCTAAACAGGTACT G 3′,
RPL13A Rev 5′ GCACGACCTTGAGGGCAGCC 3′.
Propidum iodide staining
AF’s ability to alter the cell cycle in MDA-MB-468shAhR
and Cal51shAhR cells was analyzed using a propidium
iodide (PI) staining assay according to manufacturer’s pro-
tocols (Sigma). Briefly, MDA-MB-468shAhR cells were
seeded into six-well tissue culture plates and treated with
0.1% DMSO or 25nM AF for 4, 24, 48, 72, or 120 hours.
Cal51shAhR cells were seeded into six-well tissue culture
plates and treated with 0.1% DMSO or 250nM AF for 24,
48, 72, 120, or 168 hours. Triplicate samples were col-
lected for all controls, and duplicate samples were col-
lected for all treatment groups. Cells were harvested and
fixed with EtOH up to a concentration of 70%, and kept at
4°C until PI staining. Samples were then analyzed by a
FACScalibur instrument (Becton Dickinson) for cell cycle
alterations. Data was analyzed using ModFitLT 3.2.1.
Analysis of apoptosis and DNA damage
AF’s ability to induce apoptosis and DNA damage in
MDA-MB-468 and Cal51 cells was analyzed using an
Apoptosis, DNA Damage, and Cell Proliferation flow
cytometry kit (BD, #562253), according to the manufac-
turer’s protocol. Briefly, cells were seeded into six-well
tissue culture plates in phenol red-free DMEM with 10%
charcoal-stripped FBS at 37°C and 5% CO2 and treated
with 0.1% DMSO or 25nM AF for 4, 24, 48, 72, or
120 hours. Cal51 cells were seeded into six-well tissue
culture plates and treated with 0.1% DMSO or 250nM
AF for 24, 48, 72, 120, or 168 hours. Triplicate samples
were collected for all controls, and duplicate samples
were collected for all treatment groups. Cells were col-
lected, fixed, and stained for internal antigens according
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a BD LSRII. Data was analyzed using FlowJo version 9.6.4.
Apoptosis and DNA damage in MDA-MB-468shAhR and
Cal51shAhR was analyzed using immunofluorescence
staining and western blot analysis of whole cell lysates.
Senescence-associated β-galactosidase staining
Cal51shAhR cells were maintained in the presence of 0.1%
DMSO or 250nM AF for nine days, or in the presence of
500nM of a known inducer of senescence, Doxorubicin
(Doxo) for five days, in DMEM+ 10% FBS at 37°C and 5%
CO2. At the designated time points, triplicate samples
were fixed in a 2% formaldehyde/0.2% glutaraldehyde
solution for five minutes, and then stained overnight at
37°C with an X-Gal-containing staining buffer. After two
PBS washes, samples were imaged at 10× on a Leica DM
IL inverted microscope using the Leica Applications Suite
software.
Statistical analysis
DRE Luc data are expressed as mean ± S.E.M. Two-tailed,
unpaired Student’s T Tests were performed for statistical
analysis of DRE Luciferase data using Microsoft Excel,
where * p ≤ 0.05 compared to DMSO control. qPCR data
are expressed as mean expression ± corrected S.D. Three-
parameter log versus inhibition nonlinear regression was
performed for cell counting assays using GraphPad Prism
Software (Version 5.04; Graph-Pad Software Inc., San
Diego, CA). Cell cycle data is presented as mean percent-
age of cells ± S.D. Two-tailed, unpaired Student’s T Tests
were performed for analysis of control versus treated sam-
ples to measure cell cycle alterations.
Results
ERα negative MDA-MB-468 and Cal51 human breast
cancer cells exhibit sensitivity to aminoflavone
We examined the expression of ERα and AhR in four hu-
man breast cancer cell lines (Additional file 1: Supplemen-
tal Methods; Additional file 2: Figure S1A, B). AhR was
the lowest in MCF7 cells at both the protein (Additional
file 2: Figure S1A) and mRNA level (Additional file 2:
Figure S1B). In order to assess whether ERα expression is
necessary for sensitivity to AF, we exposed MDA-MB-468
and Cal51, both ERα negative human breast cancer cell
lines, to a range of AF concentrations (Figure 1A). MDA-
MB-468 exhibited a 95% confidence interval of GI50 values
between 7.4nM and 10.7nM (Figure 1B), and Cal51 exhib-
ited a 95% confidence interval of GI50 values between
4.8nM and 34.8nM (Figure 1C). We confirm that MDA-
MB-468 is sensitive to AF [23], while the finding that
Cal51 is also exquisitely sensitive is novel. To validate this
assay, MCF7, which has been reported to be sensitive to
AF, and MDA-MB-231, which has been reported to be
resistant, were assessed [8,17,19,20]. We confirmed AFsensitivity in MCF7 (Figure 1D), and insensitivity in MDA-
MB-231 (Figure 1E). These results suggested that ERα
expression may not be a determinant of AF sensitivity in
all in vitro models, and may not be useful as a biomarker
for responsiveness to this compound.
Aminoflavone induces AhR-mediated expression of
CYP1A1, CYP1B1, and luciferase downstream of dioxin
responsive elements
To confirm the finding that AF is capable of activating
AhR signaling, 101 L hepatoma cells stably harboring
three dioxin responsive elements upstream of a luciferase
reporter were incubated with 0.1% dimethyl sulfoxide
(DMSO) or AF (100nM - 10 μM) for 18 hours. After nor-
malizing raw luciferase units to the background levels
seen in the DMSO control, we show that AF significantly
increases luciferase expression in this system (Figure 2A).
However, compared with the positive control, β-
Naphthoflavone (BNF), it is evident that AF is a weak
AhR agonist [39]. This result is consistent with the previ-
ous finding that AF has agonistic effects on AhR. Further,
it was previously shown that AhR target genes CYP1A1,
and to a lesser extent CYP1A2 and CYP1B1 are upregu-
lated in response to AF treatment, and may play role in
the metabolism of AF itself [7,8,17,19-21,25]. We went on
to examine whether AF could induce AhR target genes in
MDA-MB-468 and Cal51. Cells were treated with a range
of AF concentrations from 10nM to 10 μM, along with
1 μM of BNF as a positive control for AhR activation [39].
While MDA-MB-468 and Cal51 exhibit similar sensitiv-
ities to AF based on their GI50 values, we found that their
ability to upregulate CYP1A1 and CYP1B1 expression
after AF treatment was drastically different. AF strongly
induced CYP1A1 (Figure 2B) and CYP1B1 (Figure 2C)
expression in MDA-MB-468, but to a much lesser extent
in Cal51. Compared to MCF7, which has been shown to be
responsive to AhR ligands, MDA-MB-468 exhibits greater
induction of CYP1A1 upon AhR activation (Additional file
2: Figure S1C). Cal51 exhibits greater induction of CYP1A1
upon treatment with AhR activators as compared to MDA-
MB-231, which is AF-resistant, but the induction is less
than both MCF7 and MDA-MB-468 (Additional file 2:
Figure S1C) [7,8,17,19,20,25]. SULT1A1 expression has also
been linked to AF sensitivity [20,21]. MDA-MB-468 and
Cal51 cells express SULT1A1 basally, but its expression is
not induced by treatment with AF or BNF (Figure 2D).
Further, we have shown that knocking down AhR does not
decrease basal SULT1A1 expression in MDA-MB-468, and
only minimally alters SULT1A1 expression in Cal51
(Additional file 3: Figure S2A, B). Interestingly, direct
knockdown of SULT1A1 in these cell lines results in signifi-
cantly increased resistance to AF’s cytotoxic effects
(Additional file 1: Supplemental Methods; Additional file 3:
Figure S2C-E). Overall, these results suggest that cell
Figure 1 ERα-negative MDA-MB-468 and Cal51 human breast cancer cell lines exhibit sensitivity to AF. (A) Structure of Aminoflavone
(5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methylchromen-4-one; AF; NSC 686288). (B) GI50 (growth inhibition) mediated by AF plotted as
concentration of AF in log [M] versus number of viable MDA-MB-468 cells. Cells were treated with AF for seven days. Data is presented as a 95%
confidence interval of the GI50 value for AF. (C) GI50 (growth inhibition) mediated by AF plotted as concentration of AF in log [M] versus number
of viable Cal51 cells. Cells were treated with AF for seven days. Data is presented as a 95% confidence interval of the GI50 value for AF. (D) MCF-7
human breast cancer cells and (E) MDA-MB-231 human breast cancer cells, which are reported to be sensitive and resistant respectively, were
examined to validate the cell counting assay. Both cell lines were treated with AF for seven days.
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may exhibit AF sensitivity. Thus, active downstream AhR
signaling may not be required to confer AF sensitivity.
Endogenous levels of AhR are not required for sensitivity
to aminoflavone in MDA-MB-468 and Cal51 human breast
cancer cells
It has been previously reported that AF-sensitive MCF7
cells become resistant to AF upon attenuation of AhR sig-
naling. In addition, localization of AhR in the cellular
cytoplasm has been shown to correlate with AF sensitivity
[8,17,19,20]. As AhR may serve as a potential biomarker
for sensitivity to AF, we examined the cellular localization
as well as the requirement of endogenous levels of AhR
for AF sensitivity in MDA-MB-468 and Cal51 cells. Weshowed using immunofluorescence that MDA-MB-468
and Cal51 cells express AhR in the cytoplasm, as well as
strongly in the nucleus (Additional file 1: Supplemental
Methods; Additional file 4: Figure S3). Using MDA-MB-
468 and Cal51 harboring Dox-inducible AhR knockdown
systems (Figure 3A), we repeated cell counting assays to
determine the GI50 value of AF with and without knock
down of endogenous AhR protein. To validate the abla-
tion of the AhR pathway, we examined AhR protein
level by western blot and CYP1A1 induction after
shRNA-mediated knockdown. Western blotting using
whole cell lysate confirmed successful AhR knockdown
after treating the cells with 750 ng/mL of Dox for seven
days (Figure 3B). Correspondingly, CYP1A1 induction by
AF and BNF was attenuated in MDA-MB-468 (Figure 3C)
Figure 2 AF increases expression of a DRE-luciferase reporter, CYP1A1, and CYP1B1. (A) Quantitative representation of AF’s ability to
induce luciferase expression downstream of DRE sites in the 101 L hepatoma model. Raw luciferase data was normalized to the DMSO control
and to total protein in each sample as determined by the Bradford method. Data is presented as mean normalized luciferase activity ± S.E.M. of
triplicate samples. * p≤ 0.05 compared to DMSO control. (B) Quantitative representation of RPL13A-normalized levels of CYP1A1 gene expression
in MDA-MB-468 and Cal51 human breast cancer cell lines exposed to a range of AF concentrations and an AhR agonist as a positive control,
using SYBR-based quantitative PCR. Data is presented as mean relative mRNA level ± S.D. of triplicate samples. (C) Quantitative representation of
RPL13A-normalized levels of CYP1B1 gene expression in MDA-MB-468 and Cal51 human breast cancer cell lines exposed to a range of AF
concentrations, using SYBR-based quantitative PCR. Data is presented as mean relative mRNA level ± S.D. of triplicate samples. (D) Quantitative
representation of RPL13A-normalized levels of SULT1A1 gene expression in MDA-MB-468 and Cal51 human breast cancer cell lines exposed to a range
of AF concentrations, using SYBR-based quantitative PCR. BNF serves as a positive control. Data is presented as mean relative mRNA level ± S.D.
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http://www.biomedcentral.com/1471-2407/14/344and Cal51 (Figure 3D) after AhR knockdown by Dox
treatment.
As expected, MDA-MB-468shAhR (Figure 4A) and
Cal51shAhR (Figure 4C) were sensitive to AF when
endogenous levels of AhR protein are present, with GI50
ranges for AF of 13.1nM–17.3nM and 10.9nM–25.4nM,
respectively. Similarly, when endogenous levels of AhRprotein were decreased and AhR signaling was attenuated
upon treatment with Dox, MDA-MB-468shAhR (Figure 4B)
and Cal51shAhR (Figure 4D) exhibited GI50 values for AF
ranging from 1.7nM–2.7nM and 12.3nM–29.8nM, respect-
ively. We observed that the GI50 value for AF in MDA-
MB-468shAhR decreases upon AhR knockdown. This may
be attributed to variability in residual AhR levels post-
Figure 3 AhR knockdown in MDA-MB-468 and Cal51 decreases AhR protein and expression of downstream targets. (A) Model of Tet-On
doxycycline (Dox)-inducible AhR knockdown system engineered in MDA-MB-468 and Cal51 human breast cancer cell lines (MDA-MB-468shAhR
and Cal51shAhR). (B) Western blot of whole cell lysate from MDA-MB-468shAhR and Cal51shAhR treated with vehicle control or 750 ng/mL Dox
in the tissue culture medium for 7 days. (C) Quantitative representation of RPL13A-normalized levels of CYP1A1 gene expression in MDA-MB-
468shAhR treated with vehicle control or 750 ng/mL Dox for seven days, then treated with compound for six hours. Data is presented as mean
relative mRNA level ± S.D. of triplicate samples. (D) Quantitative representation of RPL13A-normalized levels of CYP1A1 gene expression in
Cal51shAhR treated with vehicle control or 750 ng/mL Dox for seven days, then treated with compound for six hours. Data is presented as
mean relative mRNA level ± S.D. of triplicate samples.
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tested in this model reach as low as 0.01nM, variability
in actual concentration may contribute to the apparent
decrease. If AhR confers high sensitivity of cells to AF,
knockdown of AhR is expected to increase GI50 value.
However, AhR knockdown did not greatly affect AF
sensitivity in either MDA-MB-468 or Cal51. These re-
sults suggest that an endogenous level of AhR protein
is not responsible for high AF sensitivity in MDA-MB-
468 and Cal51 human breast cancer cells. In addition, it
supports our observation that a high level of AhR target
gene induction does not necessarily predict sensitivity
to AF. Given the incomplete knockdown of AhR byshRNA, we cannot exclude the possibility that residual
AhR and AhR signaling post-knockdown is sufficient to
sustain bioactivation of AF and confer AF sensitivity. In
addition, AhR has been suggested to have extranuclear
effects [40]. We have demonstrated that treatment with
AF does not greatly modulate the phosphorylation of c-
Jun in MDA-MB-468shAhR and Cal51shAhR cells, in the
presence and absence of AhR knockdown (Additional file
1: Supplemental Methods; Additional file 5: Figure S4).
These results suggest that AF sensitivity is not directly
proportional to the endogenous level of AhR and the
downstream activation of AhR in canonical and non-
canonical ways.
Figure 4 AhR knockdown does not alter AF sensitivity in
MDA-MB-468 and Cal51. (A) GI50 (growth inhibition) mediated by
AF plotted as concentration of AF in log [M] versus number of
viable MDA-MB-468shAhR cells treated with vehicle control. All GI50
data is presented as a 95% confidence interval of the GI50 value for
AF. (B) GI50 (growth inhibition) mediated by AF plotted as concentration
of AF in log [M] versus number of viable MDA-MB-468shAhR cells
treated with 750 ng/mL Dox in the tissue culture media for seven days
prior to experiment plating (and maintained throughout the experiment).
(C) GI50 (growth inhibition) mediated by AF plotted as concentration of
AF in log [M] versus number of viable Cal51shAhR cells treated with
vehicle control. (D) GI50 (growth inhibition) mediated by AF plotted as
concentration of AF in log [M] versus number of viable Cal51shAhR cells
treated with 750 ng/mL Dox in the tissue culture media for seven days
prior to experiment plating (and maintained throughout the experiment).
All cells were treated with AF for seven days.
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mechanistic profiles in MDA-MB-468 and Cal51 human
breast cancer cells
A variety of mechanisms have been shown to underlie AF
sensitivity in various cell types, including DNA-protein
crosslinks, cytokeratin-RNA crosslinks, phosphorylation
of p53, increased expression of p21, DNA damage, react-
ive oxygen species-mediated apoptosis, and S-phase arrest
[7,8,17,19,20,22-25]. However, a majority of this work
focused on ERα-positive, AF-sensitive cell populations,
with the exception of one publication examining MDA-
MB-468 [23]. After observing GI50 values for AF in the
low nanomolar range for MDA-MB-468shAhR and Cal51-
shAhR, we chose to study the mechanism underlying AF
sensitivity at relatively low concentrations. These concen-
trations (25nM AF for MDA-MB-468shAhR and 250nM
for Cal51shAhR) were chosen based on the behavior of
the cell lines in cell counting assays. Cal51shAhR exhib-
ited static growth inhibition when treated with concentra-
tions of AF greater than 100nM. For this reason, we chose
to treat Cal51shAhR with 250nM AF. Using these concen-
trations, we examined cell cycle changes, senescence,
DNA damage, and apoptosis. Upon treatment with 25nM
AF, we observed an accumulation of MDA-MB-468shAhR
cells in S phase beginning at 4 hours and lasting until
120 hours treatment, both in the presence and absence of
AhR knockdown resulting from Dox treatement (Figure 5A).
This increase in the percentage of cells in S phase was sta-
tistically significant compared to the control in all treated
groups (p < 0.01). Cal51shAhR cells also exhibited an accu-
mulation in S-phase upon treatment with 250nM AF, both
in the presence and absence of AhR knockdown, but this
arrest appeared to be reversed over the course of 168 hour
(seven days) of treatment (Figure 5B). However, the increase
in the percentage of cells in S phase was statistically signifi-
cant at the level of p < 0.01 for the 24 hour, 48 hour, and
72 hour time points, and at the level of p < 0.05 at the
120 hour time point. There was no statistically significant
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Figure 5 AF induces cell cycle alterations in MDA-MB-468shAhR and Cal51shAhR. (A) MDA-MB-468shAhR cells were pretreated with 750 ng/mL
Dox or an equivalent amount of vehicle for seven days to induce AhR knockdown. Cells were then treated with 0.1% DMSO or 25nM AF, with or
without co-treatment with 750 ng/mL of Dox, for the corresponding length of time. DNA content was evaluated using propidium iodide staining. A
representative graph of DNA content versus cell number is shown for DMSO control (top left panel) and for the accumulation of cells in S phase (top
right panel). All data in the top panels is presented as percentage of total cells in G0/G1, S, and G2/M phase for each treatment, shown with standard
deviation. Statistical analysis in the form of Student’s T-test was used to compare the percentage of S phase cells between 0.1% DMSO-treated and
AF-treated cells was performed, but not labeled due to the stacked nature of the graph (B) Cal51shAhR cells were pretreated with 750 ng/mL Dox or
an equivalent amount of vehicle for seven days to induce AhR knockdown. Cells were then treated with 0.1% DMSO or 250nM AF, with or without
co-treatment with 750 ng/mL of Dox, for the corresponding length of time. DNA content was evaluated using propidium iodide staining. A representative
graph of DNA content versus cell number is shown for DMSO control (top left panel) and for the accumulation of cells in S phase (top right panel). All data
in the right panel is presented as percentage of total cells in G0/G1, S, and G2/M phase for each treatment, shown with standard deviation. Statistical
analysis in the form of Student’s T-test was used to compare the percentage of S phase cells between 0.1% DMSO-treated and AF-treated cells was
performed, but not labeled due to the stacked nature of the graph.
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http://www.biomedcentral.com/1471-2407/14/344correspond to the observed S phase arrest (throughout
the timecourse in MDA-MB-468shAhR, and up until the
120 hour time point in Cal51shAhR), we demonstrated an
accumulation of Cyclin A2, which is synthesized at the on-
set of DNA synthesis, in response to treatment with25nM and 250nM for MDA-MB-468shAhR and Cal51-
shAhR respectively [41] (Additional file 1: Supplemental
Methods; Additional file 6: Figure S5A, B). To examine the
underlying mechanism of AF-mediated growth arrest, we
used flow cytometry to analyze levels of the DNA damage
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http://www.biomedcentral.com/1471-2407/14/344marker, phosphorylated H2AX at serine 139 (γ-H2AX),
as well as levels of cleaved poly-ADP ribose polymerase
(PARP), which is a marker of apoptosis, in MDA-MB-
468 and Cal51 parental cells. γ-H2AX was found to be
elevated in MDA-MB-468 cells as early as four hours of
treatment with 25nM AF (Figure 6A). Further, low dose
AF treatment resulted in an increase in PARP cleavage
after five days (Figure 6A, Additional file 1: Supplemental
Methods; Additional file 6: Figure S5C). An approximate
six to nine fold increase in γ-H2AX resulted from treat-
ment with 250nM AF in Cal51 for the duration of the
compound treatment, but presence of PARP cleavage was
not evident (Figure 6B). To more thoroughly examine the
kinetics of γ-H2AX in response to AF, we stained γ-H2AX
foci in MDA-MB-468shAhR and Cal51shAhR by im-
munofluorescence, both in the presence and absence of
AhR knockdown. In these models, we performed AF dose
response, timecourses of 25nM AF and 250nM AF for
MDA-MB-468shAhR and Cal51shAhR respectively, and
recovery experiments subsequent to treatment with these
concentrations of AF. γ-H2AX stained cells were qualita-
tively analyzed for light staining, discrete foci, or diffuse
staining [22]. We did not observe a significant dependency
of DNA damage on AF dose, as γ-H2AX staining was
consistently high at low and high concentrations of AF in
both cell models in the presence and absence of AhR
knockdown (Additional file 1: Supplemental Methods;
Additional file 7: Figure S6). We also did not observe a
significant dependency of DNA damage on the length of
AF treatment. γ-H2AX staining increased at the earliest
time points in both cell models in the presence and ab-
sence of AhR knockdown, and they remained high
throughout the timecourse (Additional file 1: Supplemen-
tal Methods; Additional file 8: Figure S7). Further, it did
not appear that γ-H2AX in response to AF treatment was
reversible in MDA-MB-468shAhR and Cal51shAhR at
25nM and 250nM respectively, both in the presence and
absence of AhR knockdown (Additional file 1: Supple-
mental Methods; Additional file 9: Figure S8). Lastly, we
found that treatment of Cal51shAhR with 250nM of AF
for nine days induced the presence of senescence-
associated β-galactosidase expression, both in the pres-
ence and absence of AhR knockdown (Figure 6C). These
results showed that AF-mediated growth inhibition may
occur through varying mechanisms. While DNA damage
and S-phase cell cycle arrest occurred in both MDA-MB-
468 and Cal51 cells, the apoptotic response appeared to
occur in only MDA-MB-468, and a senescent-like pheno-
type was only observed in Cal51.
Discussion
AF is a novel anticancer drug candidate that had been inves-
tigated in multiple clinical trials, although the biomarker (s)
predictive of AF anticancer activity have not been defined.Numerous studies have investigated the effects of AF
treatment in human tumor cell lines, as well as the
mechanisms underlying sensitivity and the effects in
combination with other anticancer drugs [42]. However,
the main body of work focuses on a few model cell lines,
in particular, AF-sensitive ERα-positive MCF7. While
there seems to be a correlation between ERα expression
and AF sensitivity in the NCI 60 cell line screen and the
literature, it is imperative to fully explore the properties
of sensitive populations of cells to discover potential bio-
marker (s) for patient stratification in clinical trials. For
example, one publication suggests that ERα, while an in-
dicator of AF sensitivity, may not be a reliable predictor
of AF effectiveness in all cases, as ERα-negative MDA-
MB-468 human breast cancer cells also exhibited sensi-
tivity [23]. MDA-MB-231 and MDA-MB-453 are com-
monly used to demonstrate insensitivity to AF in ERα
negative human breast cancer cell lines. Given the poor
clinical prognosis and lack of targeted therapies associ-
ated with triple negative breast cancers, examining a
wider range of ERα-negative breast cancer cell lines to
understand AF’s effects is important.
Recent studies draw attention to the relationship be-
tween AF sensitivity and AhR signaling. AF was shown to
be an agonist of AhR signaling, and AF-induced growth
inhibition in renal and breast cancer cells is mediated by
AhR activation [7,8,17,19,20,22-25]. Our results are con-
sistent with the finding that AF is able to induce AhR sig-
naling. We showed that AF could activate a DRE-driven
luciferase reporter and induce expression of CYP1A1 and
CYP1B1 in AF-sensitive, ERα-negative MDA-MB-468 hu-
man breast cancer cells. Interestingly, we found that AF
sensitivity could be uncoupled from AhR responsiveness
as exemplified in a human breast cancer cell line, Cal51.
We first showed that Cal51 cells, while expressing high
levels of endogenous AhR protein, lack CYP1A1 and
CYP1B1 induction upon treatment with AhR activators.
Cal51 cells are sensitive to AF, exhibiting a GI50 value in
the nanomolar range. When AhR is knocked down in
Cal51shAhR, inducibility of CYP1A1 was further attenu-
ated, yet AF’s GI50 value was not greatly affected. MDA-
MB-468 cells are relatively responsive to AhR activation,
and like Cal51, they maintain sensitivity to AF after AhR
knockdown. SULT1A1 has also been implied in the bioac-
tivation of AF, and we showed that both MDA-MB-468
and Cal51 express a basal level of SULT1A1 mRNA. How-
ever, AF and BNF were unable to increase levels of this
gene. The AhR-independency of AF sensitivity in MDA-
MB-468 and Cal51 is in discrepancy with the finding that
MCF7 cells are sensitive to AF while AhR100 MCF7 cells
are AF resistant. Previous studies had shown that AhR100
cells exhibited diminished AhR protein levels, mRNA
levels, and ability to induce AhR target genes, rendering
the cell line resistant to AF [8,18,19]. The difference in AF
AB
C
Figure 6 (See legend on next page.)
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Figure 6 AF induces DNA damage in MDA-MB-468 and Cal51, apoptosis in MDA-MB-468, and cellular senescence in Cal51shAhR. The
presence of γ-H2AX and cleaved PARP (cPARP) was evaluated using fluorescent antibody based flow cytometry in MDA-MB-468 (A) and Cal51
(B) cells. Cells were treated with 25nM AF (MDA-MB-468) or 250nM AF (Cal51) for the indicated periods of time and stained with the appropriate
fluorescent antibody, per protocol requirements. Raw flow cytometry data is shown. Samples were run on a BD LSR II flow cytometer. Appropriate
fluorescent minus one samples were used to gate and analyze sample data. (C) The presence of AF-induced cellular senescence in Cal51shAhR
was examined by staining for senescence-associated β-Galactosidase. Cal51shAhR cells were pretreated with 750 ng/mL Dox or an equivalent
amount of vehicle to induce AhR knockdown. Cells were then treated with 0.1% DMSO or 250nM AF (nine days) or 100nM of a known inducer of
senescence, doxorubicin (five days), with or without co-treatment with 750 ng/mL Dox. Cells were then fixed and stained with an X-Gal-containing
staining buffer. Images taken at 10x are shown.
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cell type specific. Nonetheless, our data from parental
Cal51 as well as from Cal51shAhR and MDA-MB-
468shAhR provide strong evidence that AhR protein level,
as well as downstream AhR signaling may not be directly
predictive of AF sensitivity in all cell types. While our data
suggests that the growth inhibitory effects of AF still occur
in cells where the levels of AhR and AhR signaling are sig-
nificantly decreased, we have only examined the genomic
activity of AhR in the context of AF signaling. It is import-
ant to note that AhR has been shown to have non-genomic
kinase activity, including interactions with Src and effects
on Ca2+ as a second messenger in inflammatory pathways
[40, 43]. The potential role of AhR’s extranuclear effects in
the context of AF sensitivity has yet to be uncovered.
While MDA-MB-468 and Cal51 human breast cancer cell
lines exhibit similar GI50 values for AF, graphing the log of
AF concentration versus viable cell number shows that the
two curves differ in shape. In the graphical representation of
growth inhibition by AF in MDA-MB-468, we see that
higher concentrations of AF can eliminate viable cells com-
pletely. In contrast, some Cal51 cells can still survive even
at the highest AF concentrations. Due to the different pro-
files of their GI50 graphs, we predicted that the mechanisms
underlying AF-mediated growth inhibition would vary.
Because the growth inhibition mediated by AF in Cal51
plateaued at a positive number of viable cells as concentra-
tion increased (with the exception of the highest concen-
tration of 50 μM), we predicted that AF had a cytostatic
effect on the cells without immediately inducing cell death.
Indeed, we have reported the first instance of low dose
(250nM) AF treatment resulting in cellular senescence, as
shown using senescence-associated β-galactosidase stain-
ing, in Cal51shAhR human breast cancer cells, both in the
presence and absence of AhR knockdown. However, it has
been proposed that the permanent and irreversible arrest
characteristic of senescence is a tumor suppressing mech-
anism, and must be overcome for tumorigenesis and
immortalization of tumor cell lines [44]. The Cal51 human
breast cancer cell line is extremely interesting in that it is
tumorigenic, yet it consists of a population of cells that are
identified by a stable and normal karyotype [31]. This cell
line is to our knowledge, the only human breast cancer cell
line carrying a normal karyotype. It remains to bedetermined whether induction of cellular senescence by
AF is linked to normal karyotype. It has been shown that
different genetic abnormalities are present in three TNBC
cell lines with differing AF sensitivities [45]. MDA-MB-
231 (PTEN wild type, p53 mutant, BRCA1 wild type) is re-
sistant to AF. MDA-MB-468 (PTEN null, p53 mutant,
BRCA1 wild type) and Cal51 (PTEN null, p53 wild type,
BRCA1 wild type) are sensitive to AF. A previous study
had shown that MDA-MB-468 and Cal51 cells are more
susceptible to the cytotoxic effects of several PARP inhibi-
tors than MDA-MB-231 cells [46]. Whether the common
cytotoxicity of PARP inhibitors and AF in MDA-MB-468
and Cal51 are linked to their shared PTEN and BRCA1
status warrants further investigation.
AF induces DNA damage in both MDA-MB-468 and
Cal51 cell lines, both parental and AhR knockdown cell
lines, which is consistent with previous findings [23]. We
observed an increase in γ-H2AX in MDA-MB-468 treated
with 25nM AF as early as 4 hours using flow cytometry
(Figure 6A). We also observed DNA damage in MDA-
MB-468shAhR using immunofluorescence staining for γ-
H2AX in the presence and absence of AhR knockdown
(Additional file 7: Figure S6A, Additional file 8: Figure
S7A, Additional file 9: Figure S8A). Extensive DNA dam-
age was observed in Cal51 treated with 250nM AF as
shown by flow cytometry, and the same was shown for
Cal51shAhR using immunofluorescence staining for γ-
H2AX (Figure 6B, Additional file 7: Figure S6B, Additional
file 8: Figure S7B, Additional file 9: Figure S8B). In MDA-
MB-468shAhR and Cal51shAhR, both in the presence
and absence of AhR knockdown, we observed that the
DNA damage response (using γ-H2AX as a marker)
occurred at low concentrations and early time points, and
was irreversible at 8 hours post-removal of AF. Cal51 has
been found to display microsatellite instability as well as
mutation is mismatch repair genes, offering a potential
explanation for this apparent lack of DNA repair [47].
While DNA damage occurs in both cell lines, an apoptotic
response was only observed in AF-treated MDA-MB-468.
Conclusions
In summary, we showed that MDA-MB-468 and Cal51,
both ERα negative human breast cancer cell lines, are sen-
sitive to growth inhibition mediated by AF. This growth
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http://www.biomedcentral.com/1471-2407/14/344inhibition occurs regardless of whether or not the cells are
induced by doxycycline to decrease AhR protein levels sig-
nificantly and attenuate genomic AhR signaling. While
low-dose AF induced DNA damage and S-phase arrest in
both MDA-MB-468shAhR and Cal51shAhR, AF caused
apoptosis in MDA-MB-468shAhR, and a senescent-like
phenotype in Cal51shAhR. Our results suggest that AF
may be a viable therapeutic option for broader subtypes of
breast cancers. While the underlying mechanism of AF-
mediated growth inhibition may vary between cell lines,
and likely between individual tumors, it is encouraging
that AF, even at very low doses, is effective in more than
one TNBC cell line. At present, chemotherapy is the only
available treatment for TNBC. Given that systemic toxicity
is a recurring problem in chemotherapies, and is also the
cause of suspension for several Phase I and II clinical trials
for AF, this work suggests that further studies are needed
to identify potential biomarkers to stratify patient popula-
tions that might benefit from low dose AF treatment to
circumvent systemic toxicity.Additional files
Additional file 1: Supplemental Methods.
Additional file 2: Figure S1. Expression of AhR, ERα, and CYP1A1 in
MDA-MB-468, MDA-MB-231, Cal51, and MCF7 human breast cancer cells.
(A). Whole cell lysates were collected from MDA-MB-468, MDA-MB-231,
Cal51, and MCF7 human breast cancer cells. Western blotting indicates
the relative protein expression levels of AhR and ERα in these cell lines.
(B). Total RNA was collected from MDA-MB-468, MDA-MB-231, Cal51, and
MCF7 human breast cancer cells and reverse transcribed. qPCR was
performed for AHR and ESR1 (ERα) transcript, and the data is shown as
mean relative mRNA level normalized to RPL13A, ± S.D of triplicate values.
(C). Total mRNA was collected from MDA-MB-468, MDA-MB-231, Cal51,
and MCF7 human breast cancer cells treated with 0.1% DMSO, 1 μM AF,
or 1 μM BNF for 6 hours, and reverse transcribed. qPCR was used to
determine the induction of the CYP1A1 gene (normalized to RPL13A),
shown as ± S.D of triplicate values.
Additional file 3: Figure S2. AhR knockdown results in minimal alteration
of SULT1A1 expression in MDA-MB-468shAhR and Cal51shAhR cells, while an
efficient knockdown of SULT1A1 results in an increase in resistance to
cytotoxicity mediated by AF. Total RNA was collected from MDA-MB-
468shAhR (A) and Cal51shAhR (B) cells pretreated with 750 ng/mL Dox or
vehicle for seven days to induce AhR knockdown, and subsequently
treated with 0.1% DMSO, 5 μM BNF, or 5 μM AF for six hours. qPCR was
performed for SULT1A1, and the data is shown as mean relative mRNA
level normalized to RPL13A± S.D. of triplicate values. SULT1A1 expression
is minimally effected by AhR knockdown. (C). Total RNA was collected
from parental MDA-MB-468 and Cal51 cells infected with lentivirus
containing a scrambled shRNA or shRNA directed toward SULT1A1. qPCR
was performed for SULT1A, and the data is shown as mean relataive
mRNA level normalized to RPL13A± S.D. of triplicate values. SULT1A1 knock-
down appears to be efficient at the transcript level. 3-[4,5-dimethylthiazol-2-
yl]-2,5 diphenyl tetrazolium bromide (MTT) assays were performed in (D)
MDA-MB-468 cells harboring SULT1A1 shRNA and (E) Cal51 cells harboring
SULT1A1 shRNA. Cells were plated in a 96-well format and treated with
0.1% DMSO or varying concentrations of AF for 48 hours prior to incubation
with MTT. Knockdown of SULT1A1 results in enhanced resistance to
AF-mediated cytotoxicity. **p < 0.01, *p < 0.05.
Additional file 4: Figure S3. AhR is localized to both the cytoplasm and
nucleus in Cal51 and MDA-MB-468 human breast cancer cells.
Immunofluorescence for AhR was performed in Cal51 and MDA-MB-468,showing that AhR localizes to the cytoplasm, but also strongly in the
nuclei of these cells. Images were acquired at 40×.
Additional file 5: Figure S4. AF does not have significant effects on JNK
activity in MDA-MB-468shAhR and Cal51shAhR cells. (A). Whole cell lysates
were collected from MDA-MB-468shAhR pretreated with 750 ng/mL Dox
and subsequently treated with 25nM AF, in the presence and absence of
AhR knockdown by maintaining 750 ng/mL Dox or vehicle in the media.
Western blotting shows that compared total c-Jun levels, phosphorylated
c-Jun (p-c-Jun) does not appear to be affected by AF treatment. (B).
Whole cell lysates were collected from Cal51shAhR pretreated with
750 ng/mL Dox and subsequently treated with 250 nM AF, in the
presence and absence of AhR knockdown by maintaining 750 ng/mL
Dox or vehicle in the media. Western blotting shows that compared total
c-Jun levels, phosphorylated c-Jun (p-c-Jun) does not appear to be
affected by AF treatment. We observe a decrease of total c-Jun protein at
the 7 day time point. HSP90 was used as a loading control.
Additional file 6: Figure S5. Cyclin A2 increases in response to AF
treatment in MDA-MB-468shAhR and Cal51shAhR cells. Whole cell lysates
were collected from MDA-MB-468shAhR (A) and Cal51shAhR (B) pretreated
with 750 ng/mL Dox and subsequently treated with 25nM AF or 250nM AF
respectively, in the presence and absence of AhR knockdown by maintaining
750 ng/mL Dox or vehicle in the media. Western blotting shows that
compared to control, AF causes an increase in Cyclin A2 protein in MDA-MB-
468shAhR during the timecourse, both in the presence and absence of AhR
knockdown, consistent with the observed S-phase cell cycle arrest. Cyclin A2
protein levels initially increase in Cal51shAhR, then decrease at the end of the
timecourse, both in the presence and absence of AhR knockdown. This is
consistent with the S-phase arrest observed in cell cycle analysis, with the
7 day (168 hour) time point having no statistically significant increase in
percentage of S-phase cells. (C). Whole cell lysates were collected from
MDA-MB-468shAhR pretreated with 750 ng/mL Dox and subsequently
treated with 25nM AF, in the presence and absence of AhR knockdown
by maintaining 750 ng/mL Dox or vehicle in the media. Western blotting
shows that after 48 hours, 25nM AF causes PARP cleavage.
Additional file 7: Figure S6. The intensity of γ-H2AX staining is not
proportional to AF dose in MDA-MB-468shAhR and Cal51shAhR cells.
MDA-MB-468shAhR (A) and Cal51shAhR (B) were treated with a range of
AF concentrations and then subjected to immunofluorescence staining
for γ-H2AX. FITC (γ-H2AX) images were overlaid upon DAPI (nuclear), and
at least thirty individual cells were assessed for intensity of γ-H2AX staining.
We observed that γ-H2AX staining that remained constant regardless of AF
dose.
Additional file 8: Figure S7. γ-H2AX staining intensity is not time
dependent in MDA-MB-468shAhR and Cal51shAhR cells. MDA-MB-468shAhR
(A) and Cal51shAhR (B) were treated with 25nM or 250nM AF respectively
for six hours, then subjected to immunofluorescence staining for γ-H2AX.
FITC (γ-H2AX) images were overlaid upon DAPI (nuclear), and at least
thirty individual cells were assessed for intensity of γ-H2AX staining. We
observed that γ-H2AX staining remained relatively constant over the
timecourse.
Additional file 9: Figure S8. γ-H2AX staining intensity is not reversed by
the removal of AF for eight hours in MDA-MB-468shAhR and Cal51shAhR
cells. MDA-MB-468shAhR (A) and Cal51shAhR (B) were treated with 25nM
and 250nM AF respectively for six hours, then was replaced with untreated
media for various lengths of time. Samples were subjected to immunofluor-
escence staining for γ-H2AX. FITC (γ-H2AX) images were overlaid upon DAPI
(nuclear), and at least thirty individual cells were assessed for intensity of γ-
H2AX staining. We observed that even after eight hours after AF removal, γ-
H2AX staining persists, indicating that DNA damage mediated by AF may be
irreversible in these cell lines.
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